Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes

NCT02005848 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

New Onset Type-1 Diabetes

Interventions

BIOLOGICAL: Alpha-1 Antitrypsin
OTHER: Placebo

Sponsor

Kamada, Ltd.